ROP
62
3
EFX
38
2
AVY
53
3
MCD
52
2
SYY
53
4
PVH
62
5
UPS
60
9
DTE
56
2
CSX
60
3
GE
67
2
PRGO
39
3
RIG
60
2
NWS
66
-3
HOG
35
2
AIV
72
2
MHK
49
4
KLAC
47
4
CFG
70
6
YUM
47
3
ORCL
65
-2
ROP
62
3
EFX
38
2
AVY
53
3
MCD
52
2
SYY
53
4
PVH
62
5
UPS
60
9
DTE
56
2
CSX
60
3
GE
67
2
PRGO
39
3
RIG
60
2
NWS
66
-3
HOG
35
2
AIV
72
2
MHK
49
4
KLAC
47
4
CFG
70
6
YUM
47
3
ORCL
65
-2
Financhill
Back

NovaBay Pharmaceuticals 10K Form

Sell
28

NBY
NovaBay Pharmaceuticals

Last Price:
0.69
Seasonality Move:
-0.57%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive NBY News And Ratings

See the #1 stock for the next 7 days that we like better than NBY

NBY Financial Statistics

Sales & Book Value

Annual Sales: $14.73M
Cash Flow: $-2.06M
Price / Cash Flow: 0
Annual Sales: $0.22
Price / Book: 3.12

Profitability

EPS (TTM): -35.79620
Net Income (TTM): $-10.12M
Gross Margin: $7.9M
Return on Equity: -461.38%
Return on Assets: -144.37%

NovaBay Pharmaceuticals Earnings Forecast

Key NovaBay Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 21 years for NBY is 53.61%.
  • The Selling, General & Administrative Expenses for NBY have been equal to 87.12% of Gross Profit Margin.
  • The Research & Development expenses have been 0.46% of Revenue.
  • The Net Earning history of NBY is -65.46% of Total Revenues.
  • Per Share Earnings over the last 21 years have been positive in 11 years.

NovaBay Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYAM
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: NBY
CUSIP: 66987P
Website: novabay.com

Debt

Debt-to-Equity Ratio: 0.05
Current Ratio: 1.15
Quick Ratio: 0.75

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

NBY Technical Analysis vs Fundamental Analysis

Sell
28
NovaBay Pharmaceuticals (NBY) is a Sell

Is NovaBay Pharmaceuticals a Buy or a Sell?